Improved antimicrobial activity of linezolid against vancomycin- intermediate Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 4207-4208

  Watanabe, Yukiko ^a   Neoh, Hui Min ^a   Cui, Longzhu ^a   Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 55849125073     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00676-08     Document Type: Letter

References (12)

1. Asada, K., Y. Inaba, E. Tateda-Suzuki, K. Kuwahara-Arai, T. Ito, and K. Hiramatsu. 1995. Evolution and resistance expression of MRSA. Evaluation of beta-lactam antibiotics against a set of isogenic strains with different types of phenotypic expression. Acta Biochim. Pol. 42:517-524.
2. Cui, L., and K. Hiramatsu. 2003. Vancomycin-resistant Staphylococcus aureus, p. 187-212. In A. C. Fluit and F. J. Schmitz (ed.), MRSA: current perspectives. Caister Academic Press, Norfolk, England.
3. Cui, L., X. Ma, K. Sato, K. Okuma, F. C. Tenover, E. M. Mamizuka, C. G. Gemmell, M. N. Kim, M. C. Ploy, N. El-Solh, V. Ferraz, and K. Hiramatsu. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14.
4. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.
5. Diekema, D. J., and R. N. Jones. 2001. Oxazolidinone antibiotics. Lancet 358:1975-1982.
6. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
7. Hiramatsu, K., M. Kapi, Y. Tajima, L. Cui, S. Trakulsomboon, and T. Iso. 2004. Advances in vancomycin resistance: research in Staphylococcus aureus, p. 289-298. In M. Alekshun, P. McDermott, and D. White (ed.), Frontiers in antibiotic resistance: a tribute to Stuart B. Levy. ASM Press, Washington, DC.
8. Kuroda, M., T. Ohta, I. Uchiyama, T. Baba, H. Yuzawa, I. Kobayashi, L. Cui, A. Oguchi, K. Aoki, Y. Nagai, J. Lian, T. Ito, M. Kanamori, H. Matsumaru, A. Maruyama, H. Murakami, A. Hosoyama, Y. Mizutani-Ui, N. K. Takahashi, T. Sawano, R. Inoue, C. Kaito, K. Sekimizu, H. Hirakawa, S. Kuhara, S. Goto, J. Yabuzaki, M. Kanehisa, A. Yamashita, K. Oshima, K. Furuya, C. Yoshino, T. Shiba, M. Hattori, N. Ogasawara, H. Hayashi, and K. Hiramatsu. 2001. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 357:1225-1240.
9. Patel, J. B., L. A. Jevitt, J. Hageman, L. C. McDonald, and F. Tenover. 2006. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42:1652-1653.
10. Ruef, C. 2004. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 32:315-327.
11. Sakoulas, G., J. Alder, C. Thauvin-Eliopoulos, R. C. Moellering, Jr., and G. M. Eliopoulos. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585.
12. Wunderink, R., J. Rello, S. Cammarata, R. Croos-Dabrera, and M. Kollef. 2003. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789-1797.